B1 Vertaisarvioimaton kirjoitus tieteellisessä lehdessä
Drug reaction with eosinophilia and systemic symptoms after ocrelizumab therapy
Tekijät: Marjo Nylund, Tytti Vuorinen, Laura Airas
Kustantaja: Elsevier
Julkaisuvuosi: 2020
Journal: Multiple Sclerosis and Related Disorders
Tietokannassa oleva lehden nimi: Multiple sclerosis and related disorders
Lehden akronyymi: Mult Scler Relat Disord
Artikkelin numero: 102058
Vuosikerta: 42
Sivujen määrä: 3
ISSN: 2211-0348
eISSN: 2211-0356
DOI: https://doi.org/10.1016/j.msard.2020.102058
Tiivistelmä
We report here on a young woman with multiple sclerosis, who developed a condition with eosinophilia and swelling of limbs seven weeks after initiation of ocrelizumab treatment. We consider her drug reaction to be compatible with a drug reaction with eosinophilia and systemic symptoms (DRESS), also called drug-induced hypersensitivity syndrome. She was treated with antihistamine and corticosteroid treatments, and recovered fully within three months of symptom onset. Ocrelizumab was not re-initiated. We are not aware of other DRESS-like cases related to ocrelizumab treatment.
We report here on a young woman with multiple sclerosis, who developed a condition with eosinophilia and swelling of limbs seven weeks after initiation of ocrelizumab treatment. We consider her drug reaction to be compatible with a drug reaction with eosinophilia and systemic symptoms (DRESS), also called drug-induced hypersensitivity syndrome. She was treated with antihistamine and corticosteroid treatments, and recovered fully within three months of symptom onset. Ocrelizumab was not re-initiated. We are not aware of other DRESS-like cases related to ocrelizumab treatment.